LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

8.28 -0.24

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.27

Massimo

8.46

Metriche Chiave

By Trading Economics

Entrata

5.1M

5.1M

Vendite

18M

163M

Margine di Profitto

3.113

Dipendenti

580

EBITDA

-84M

-62M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+110.59% upside

Dividendi

By Dow Jones

Utili prossimi

3 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-88M

1.7B

Apertura precedente

8.52

Chiusura precedente

8.28

Notizie sul Sentiment di mercato

By Acuity

32%

68%

50 / 371 Classifica in Healthcare

BioCryst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 set 2025, 23:07 UTC

Acquisizioni, Fusioni, Takeovers

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2 set 2025, 22:10 UTC

I principali Market Mover

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2 set 2025, 21:47 UTC

Utili

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2 set 2025, 16:52 UTC

I principali Market Mover

CleanCore Solutions Shares Drop After $175 Million Private Investment

2 set 2025, 22:47 UTC

Discorsi di Mercato

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2 set 2025, 21:40 UTC

Acquisizioni, Fusioni, Takeovers

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2 set 2025, 21:07 UTC

Utili

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2 set 2025, 21:07 UTC

Utili

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2 set 2025, 21:05 UTC

Utili

Couche-Tard 1Q Rev $17.35B >ATD.T

2 set 2025, 21:05 UTC

Utili

Couche-Tard 1Q Adj EPS 78c >ATD.T

2 set 2025, 21:05 UTC

Utili

Couche-Tard 1Q EPS 82c >ATD.T

2 set 2025, 21:05 UTC

Utili

Couche-Tard 1Q Net $782.5M >ATD.T

2 set 2025, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

2 set 2025, 20:53 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2 set 2025, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 set 2025, 20:27 UTC

Utili

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2 set 2025, 20:24 UTC

Acquisizioni, Fusioni, Takeovers

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2 set 2025, 20:18 UTC

Acquisizioni, Fusioni, Takeovers

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2 set 2025, 20:17 UTC

Acquisizioni, Fusioni, Takeovers

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2 set 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2 set 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2 set 2025, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2 set 2025, 19:55 UTC

Utili

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2 set 2025, 19:50 UTC

Acquisizioni, Fusioni, Takeovers

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2 set 2025, 19:09 UTC

Discorsi di Mercato

Oil Futures Gain on Geopolitical Premium -- Market Talk

2 set 2025, 19:00 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2 set 2025, 18:12 UTC

Discorsi di Mercato

Gold Pushes To New Record -- Market Talk

2 set 2025, 17:04 UTC

Discorsi di Mercato

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2 set 2025, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Confronto tra pari

Modifica del prezzo

BioCryst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

110.59% in crescita

Previsioni per 12 mesi

Media 17.5 USD  110.59%

Alto 30 USD

Basso 12 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioCryst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

50 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.